State ordering guide

Sourcing Exosomes in Illinois

Licensed Illinois practices order Kimera exosome material from ExaVeyra as research-grade product, shipped cold-chain from Miami Beach with lot traceability on every vial and a certificate of analysis issued for every lot and provided on request. Illinois buyers need their own professional license and NPI; the nonresident pharmacy and wholesale distributor licenses the Illinois Department of Financial and Professional Regulation issues sit with the shipping supplier rather than with the purchasing practice.

Two Illinois points are worth settling early. The state’s 2007 stem cell act is a research funding law that creates a grant program, not a practice statute, so there is no state definition to read exosomes into or out of. And one agency, IDFPR, issues both of the licenses a supplier needs, which makes confirming a supply chain a single inquiry rather than two.

At a glance

Summary of exosome sourcing considerations for Illinois.
QuestionAnswer
Does ExaVeyra ship to Illinois?Yes. Cold-chain from Miami Beach, as we do to all 50 states
Cold-chain transit from Miami1 to 3 business days
State regenerative-medicine statuteNone
Does that statute reach exosomes?No. Its definition is written around cells; exosomes are acellular and governed federally
Physician delegation required to hand off medical actsNo
Who holds the wholesale distribution permitThe supplier, not the purchasing practice
What ExaVeyra supplies hereKimera exosome material and 503A compounded preparations
Last reviewed11 September 2026

Ordering from Illinois

ExaVeyra ships to licensed practices in all 50 states, Illinois included. Distribution-side licensing is the supplier’s obligation rather than the purchasing practice’s, so your practice orders against its own professional license and NPI, and ExaVeyra confirms the destination-specific licensure of its supply chain before a first order ships. What changes state to state is how the state regulates who performs a procedure and how the practice itself is owned, while federal law governs the product itself.

What your practice provides

  • An active Illinois professional license in good standing, verifiable through the IDFPR license lookup.
  • A valid NPI, which ExaVeyra verifies at account setup.
  • A signed research-use acknowledgment on file for exosome material.
  • An Illinois Certificate of Resale under 35 ILCS 120 if the practice is purchasing for resale rather than for use in its own operations.

How the state permits wholesale distribution

Illinois licenses the out-of-state supplier through IDFPR on two tracks, both held by the supplier rather than by the purchasing practice. Under 225 ILCS 85/16a the Department licenses nonresident pharmacies, meaning pharmacies located outside Illinois that dispense medications for Illinois residents and mail, ship or deliver prescription medications into the state. The license is granted on six certifications: that the pharmacy is licensed where it dispenses, the identities of its principal officers and the pharmacists dispensing into Illinois, compliance with the directions of every board that licenses it, records of Illinois dispensing kept separately retrievable, cooperation with the Board and the Department, and a toll-free line staffed at least six days a week for forty hours, whose number must appear on the label of every container shipped into the state. Under 225 ILCS 120/25(a) every non-resident wholesale distributor must be licensed in Illinois if it ships prescription drugs into the state, and the application discloses ownership, every facility used for storage and handling, all licenses held in other states, a designated representative with fingerprints, and minimum liability insurance. Both acts carry a repeal date of 1 January 2028, which is the Illinois sunset convention for professional licensing acts rather than a scheduled end of the requirement.

225 ILCS 85/16a; 225 ILCS 120/25 · Illinois Department of Financial and Professional Regulation

Illinois regenerative-medicine law

Illinois has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.

Illinois did legislate on stem cells, and the act is easy to mistake for a practice law. Public Act 95-519 created the Stem Cell Research and Human Cloning Prohibition Act, 410 ILCS 110, effective 1 January 2008. Its operative sections state a policy permitting research involving embryonic, germ and adult stem cells, direct that such research may receive public funds, and establish the Illinois Regenerative Medicine Institute Program within the Department of Public Health to award grants to Illinois medical research institutions. It governs research funding and research conduct rather than the delivery of services in a practice, so an Illinois practice adding a service line finds its rules in the Medical Practice Act, the Nurse Practice Act, the Physician Assistant Practice Act and the Department’s guidance to medical spas.

How this applies to exosomes

Illinois has no statute that authorises or requires a disclosure for stem cell services in a practice, and its 2007 act concerns research institutions and grant funding, so there is no state definition to read exosomes into or out of. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. One Illinois document does address the adjacent category directly and should be read before planning a service line: IDFPR’s consumer warning of 8 March 2019 records the Department’s position that only a physician licensed under the Medical Practice Act may order and administer stem cell injections, and that advanced practice registered nurses and physician assistants cannot administer injectables without physician supervision and delegation. That warning addresses stem cell injections. Exosomes are acellular extracellular vesicles rather than cells, and neither the warning nor any Illinois statute says whether the position extends to them. Whether it reaches a particular service is a question for the practice, its counsel and the Department. ExaVeyra supplies Kimera material for topical aesthetic use in clinics and for research applications, with lot documentation and a certificate of analysis for every lot.

Read the statute

Who can handle product in a Illinois practice

Illinois runs on two routes to the same act. A physician-led practice delegates under 225 ILCS 60/54.2, with the delegating physician responsible for keeping the task inside their own scope and inside the delegate’s licensing Act. An APRN with full practice authority acts on their own authority within nursing scope and may themselves delegate selected nursing interventions. Sitting across both is the category-specific position IDFPR took in 2019 on stem cell injections, which the statute note above sets out. Confirm which route your practice is relying on, and for which services, with Illinois counsel before the first session.

Delegation scope by license type in Illinois.
RoleScope under state law
MD / DOPhysicians licensed to practise medicine in all its branches perform medical acts within their scope and are the source of delegation. Under 225 ILCS 60/54.2 a physician may delegate patient care tasks to a licensed practical nurse, a registered professional nurse or another licensed person practising within their own licensing Act, and in an office setting within a physician-patient relationship may delegate to an unlicensed person with appropriate training and experience provided a licensed health care professional is on site. No physician may delegate a task that a statute or rule requires a physician to perform. Any delegated task must sit within the scope, education, training or experience of the delegating physician.
NP / APRNAdvanced practice registered nurses may hold full practice authority under 225 ILCS 65/65-43. It is not automatic: the APRN files a notarised attestation of at least 250 continuing education or training hours and at least 4,000 clinical hours after first attaining national certification, with the clinical experience in the area of certification and in collaboration with a physician. An APRN who holds it practises without a written collaborative agreement in all settings consistent with national certification and prescribes legend drugs and Schedule II through V controlled substances. Two limits are stated in the statute and repeated in the 2025 medspa memo: local anaesthetic only, and no operative surgery. Without the attestation, a written collaborative agreement under 225 ILCS 65/65-35 is required outside a hospital, federally qualified health center or ambulatory surgical treatment center.
PAPhysician assistants practise under a written collaborative agreement with a supervising physician under the Physician Assistant Practice Act, and the collaborating physician maintains the guidelines for delegated prescriptive authority in that agreement. IDFPR’s 2019 warning states that physician assistants cannot administer injectables without physician supervision and delegation.
RNRegistered professional nurses delegate under 225 ILCS 65/50-75, which the 2025 medspa memo sets out: an RN may delegate nursing interventions to other registered nurses, licensed practical nurses and unlicensed personnel only on a comprehensive nursing assessment that weighs the stability and condition of the patient, the potential for harm, the complexity of the intervention, the predictability of the outcome and the competency of the person receiving the delegation, and may refuse, stop or rescind a delegation at any time. Delegation of medication administration to unlicensed personnel is confined to community and in-home settings and to oral, subcutaneous, topical or transdermal routes.

Good faith examination

Illinois does not use the phrase “good faith examination” as a statutory term. The functional requirement follows from the delegation rules and from the laser statement: a delegated task must sit within a physician-patient relationship and within the delegating physician’s own scope, and for laser procedures IDFPR states that the physician must examine the patient and determine an appropriate course of treatment before the procedure is performed. An APRN with full practice authority may perform the assessment and establish the plan within their own scope. Confirm current expectations with IDFPR.

Ownership and clinic licensing

Illinois is a corporate practice state, and the structure question is settled before the clinical one. A general business corporation may not employ physicians to practise medicine; the entity is ordinarily a professional service corporation, a professional limited liability company or a medical corporation whose ownership is restricted to licensed professionals, formed under the Professional Service Corporation Act and the Medical Corporation Act. The joint IDFPR and Illinois Department of Public Health memo on medical spa services, updated 30 October 2025, is the document that applies these rules to this setting: physicians licensed to practise medicine in all its branches may operate a medspa, perform cosmetic procedures that affect the living layers of the skin, prescribe and administer, and supervise and delegate. The same memo states that a salon registration issued by IDFPR cannot be used to operate a medspa, and that cosmetologists, estheticians and nail technologists are prohibited from any technique intended to affect the living layers of the skin. Structure the entity with Illinois counsel before opening.

Cold chain into Illinois

Shipments dispatch from our Miami Beach facility under validated temperature monitoring, and delivery into Illinois is scheduled to avoid a weekend hold at the carrier hub.

Metros ExaVeyra supplies in Illinois.
MetroCountyNotes
ChicagoCookLargest concentration of dermatology, aesthetic and concierge practices in the state.
Naperville and AuroraDuPage and KaneWestern suburban corridor with a dense med spa market.
SchaumburgCookNorthwest suburban cluster serving the O’Hare corridor.
PeoriaPeoriaCentral Illinois hub with a broad clinical mix.
SpringfieldSangamonState capital market with hospital-affiliated and independent practices.
RockfordWinnebagoNorthern Illinois market on the Wisconsin border.
  • Illinois orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
  • Inspect the temperature indicator on arrival and contact us before use if the shipment reads outside range.
  • Storage and handling conditions for each product are stated on its Certificate of Analysis.

Illinois sourcing questions

Does Illinois have a stem cell law that covers exosomes?
Not one that reaches practice. Public Act 95-519 created the Stem Cell Research and Human Cloning Prohibition Act, 410 ILCS 110, which states a policy permitting research, allows public funding for it, and establishes the Illinois Regenerative Medicine Institute grant program for medical research institutions. It regulates research and its funding rather than services delivered in a practice. Exosome products are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
Does my Illinois clinic need a pharmacy or wholesale distributor license to buy exosomes?
No. Both licenses are held by the out-of-state supplier and both are issued by IDFPR: the nonresident pharmacy license under 225 ILCS 85/16a and the wholesale drug distributor license under 225 ILCS 120/25. Your practice orders against its own professional license and NPI, and ExaVeyra confirms destination licensure across its supply chain before a first order ships.
Can my Illinois practice source 503A compounded peptides through ExaVeyra?
Yes. Compounded formulations are prepared by our 503A pharmacy partner, a compounding pharmacy licensed by the Texas State Board of Pharmacy, and it holds the Illinois nonresident pharmacy license that 225 ILCS 85/16a requires of an out-of-state pharmacy shipping prescription medications into the state. That license sits with the pharmacy rather than with your practice; IDFPR’s license lookup is where a practice confirms it, and we confirm current status for your destination before the first prescription is placed.
Does IDFPR’s stem cell warning mean only a physician can handle exosome material?
IDFPR’s warning of 8 March 2019 records the Department’s position that only a physician licensed under the Medical Practice Act may order and administer stem cell injections, and that APRNs and physician assistants cannot administer injectables without physician supervision and delegation. It addresses stem cell injections. Exosomes are acellular extracellular vesicles rather than cells, and neither that warning nor any Illinois statute says whether the position extends to them. Treat it as the most on-point Illinois guidance for the adjacent category and settle the question for your own services with Illinois counsel and the Department before proceeding.
Can a nurse practitioner run an aesthetic practice in Illinois?
Within nursing scope, if the authority has been established. 225 ILCS 65/65-43 grants full practice authority to an APRN who files a notarised attestation of at least 250 continuing education or training hours and at least 4,000 clinical hours after national certification, and the joint IDFPR and IDPH medspa memo of 30 October 2025 recognises that authority in this setting. The statute limits it to local anaesthetic and excludes operative surgery. Without the attestation, a written collaborative agreement under 225 ILCS 65/65-35 is required outside a hospital, FQHC or ambulatory surgical treatment center. Ownership is a separate question: Illinois restricts the practice of medicine to professional entities owned by licensed professionals.
What does ExaVeyra verify before opening an Illinois account?
An active Illinois professional license checked through the IDFPR lookup, a valid NPI, and a signed research-use acknowledgment for exosome material. Practices buying for resale also provide an Illinois Certificate of Resale.
How should exosome material be handled on arrival?
Check the temperature indicator included with the shipment before the vials go into storage, and move them to their storage condition promptly. If the indicator reads outside range, contact us before use rather than storing the shipment. Storage and handling conditions for each product are stated on its Certificate of Analysis, and every vial carries its lot number.

Material available to licensed Illinois practices

Kimera Labs preparations distributed by ExaVeyra, characterised on the certificate of analysis supplied with every lot. Research-grade material for licensed practices; the practitioner determines clinical use.

  • Luxir

    1 Trillion Microvesicles · 5 Trillion Microvesicles

    Available formats: 1.0 mL, 5.0 mL

  • Luxir+

    3 Trillion Microvesicles · 15 Trillion Microvesicles

    Available formats: 1.0 mL, 5.0 mL

  • Kiara

    3 mg secretome · 15 mg secretome

    Available formats: 1.0 mL, 5.0 mL

  • Vive

    2 Trillion Microvesicles

    Available formats: 5.0 mL

Characterisation and lot documentation

Sources

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic treatments in clinics and for medical, molecular biology, and biochemistry research applications, and are not tissue products as defined by FDA guidelines.

Reference only. Not legal or medical advice.

The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Read the full disclaimer

ExaVeyra Sciences publishes these guides as a reference for licensed practitioners. They summarize publicly available federal and state requirements as those requirements read on the review date shown above. The content is provided for general informational purposes only and does not constitute legal, medical, or regulatory advice, and it does not establish that any particular product or practice is compliant.

No attorney-client relationship, and no professional or clinical relationship of any kind, is created by accessing these materials. ExaVeyra Sciences is a supplier of research-use materials. It is not a law firm, it is not a regulatory consultant, and it takes no part in any diagnosis, treatment decision, or plan of care. Each practitioner is responsible for retaining their own legal counsel and for determining, with that counsel and the applicable state licensing boards, how the requirements described here apply to the services, staffing, and structure of their own practice.

Statutes, regulations, board rules, and agency positions are subject to amendment, supersession, and reinterpretation. ExaVeyra Sciences makes no representation or warranty as to the accuracy, completeness, timeliness, or applicability of this content to any particular practice. Citations and links to third-party sources are provided for convenience only and do not constitute an endorsement of their content.

The practitioner and the practice are solely responsible for compliance with all applicable licensing, scope of practice, supervision, ownership, facility, recordkeeping, and tax requirements, and for all clinical decisions, including the suitability of any material for a given patient. To the fullest extent permitted by law, ExaVeyra Sciences disclaims all liability for any action taken or not taken in reliance on this content.